- Home
- ESEA vs STRO Comparison
ESEA vs STRO Comparison
Compare ESEA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | STRO |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.0M | 332.8M |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ESEA | STRO |
|---|---|---|
| Price | $76.46 | $14.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $62.00 | $31.33 |
| AVG Volume (30 Days) | 24.2K | ★ 253.7K |
| Earning Date | 06-17-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $51.00 | $0.72 |
| 52 Week High | $79.67 | $43.85 |
Technical Indicators
Market Signals| Indicator | ESEA | STRO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 20.09 |
| Support Level | N/A | $12.85 |
| Resistance Level | N/A | $17.33 |
| Average True Range (ATR) | 0.00 | 1.08 |
| MACD | 0.00 | -0.31 |
| Stochastic Oscillator | 0.00 | 1.10 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.